OwkinAI Drug Development Solutions
We unlock insights from multimodal datasets created and curated by world-class medical academic centers
In collaboration with researchers, we train AI models for optimizing clinical trials, identifying patient subgroups, and biomarker discovery. Because the promise of AI for drug development begins with the highest quality data.Get in touch
We help you meet clinical research challenges
Leveraging our partner datasets, we deploy state-of-the-art, interpretable AI to refine our understanding of diseases. We build machine learning models (70+) across a variety of therapeutic areas that support drug development efforts and market access with:
AI patient identification tools
Power precision medicine across the development pipeline
The Owkin difference
Critical clinical context and unique data network
Cutting edge technology to prioritize privacy
Unique combinations of data types for the complete picture
The black box demystified for better understood outcomes
Better Identification of High-Risk Patients with Breast Cancer in the Race AI Project
Breast cancer, when discovered early, has a favorable long-term prognosis. Nevertheless, the incidence of breast cancer is high, and approximately 10% patients relapse after initial treatment each year. Currently, no cure exists for these patients, as a result the disease goes into a “chronic” phase with long-term treatment and management.
Together with Gustave Roussy in Paris, France, we have developed an AI diagnostic tool to better identify these high risk patients. Should it be novel hormonal therapies, additional chemotherapy, or other innovative treatments, we are now more able to accelerate the clinical utility of certain treatments and give the patient the best possible care pathway.
“Thanks to this solution we now have a better understanding of the underlying mechanism of highly aggressive tumors and the treatment needs for these patients. Identifying very high risk patients earlier will enable us to adjust the therapeutic strategy for more favorable patient outcomes.”
Prediction of genomic defects from histology images: better prediction of PARP inhibitor benefits in patients with Ovarian Cancer
Ovarian cancer is the first cancer where DNA repair defects in tumors were identified as a target for a new generation of drugs that inhibit PARP activity. However, current methods to identify these defects, based on genomic sequencing, are costly and neither sensitive nor specific enough.
Together with Gustave Roussy in Paris, France, we are developing an Patient Identification Tool that uses routine histology images to recognize and understand tumors with these genomic defects, and subsequently identify patients who could benefit from this treatment in both 1st line and relapsed settings. Furthermore, we can use this novel AI approach across many cancers to better identify patients eligible for targeted therapies.
Image caption: HRD score for scale. Images of survival curves without Drug name use PARP inhibitor instead.
“Such a tool works using little tumor tissue, could easily be used in any center, and answers an urgent need for robust and clinically feasible predictive biomarkers of PARPi benefit in ovarian cancer and beyond.”
Our therapeutic focus areas
Owkin partners focus their research on specific therapeutic areas, pathways, or mutations. As such, we create targeted alliances designed to answer some of the most challenging research questions for a myriad of unmet medical needs.
Explore how we boost medical research with Innovative Collaboration.